Study S002261

A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02617654
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 18
Start: 2015-11
Primary completion: 2020-09
Lead sponsor: Per-Ola Carlsson
Conditions: Type 1 Diabetes
Interventions: DRUG:Liraglutide; DRUG:Placebo for liraglutide
Results posted: FALSE

Registered primary outcomes

The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production [52 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.